ArticleJournal of Cancer2025

Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study.

Martin Svaton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.